Induction: 300 mg IV wk 0, wk 2, wk 6, then maintenance 300 mg every 8 wks OR following at least 2 IV infusions, 108 mg SC every 2 wks†
Patients who experience a disease flare or are non-responsive, a shorter infusion interval (q 4 wks) may be considered.
TIME REQUIRED
1–2 hrs for infusion
< 5 min SC injection
ROUTINE
MONITORING
Patients should be monitored for any new onset or worsening of neurological signs and symptoms
Liver enzymes – transaminases and bilirubin. Annual cervical cancer screening – pap test Annual skin exam – skin malignancies Influenza vaccine recommended May consider therapeutic drug monitoring (TDM) if available Screening for osteoporosis with bone mineral density testing periodically after diagnosis